This message was sent to ##Email##
To advertise in this publication please click here
|
|
|
.ACCOUNTABLE CARE ORGANIZATIONS
Evaluation of Medicare alternative payment models: What the data show
Health Affairs
The COVID-19 pandemic has impacted every aspect of life in the U.S. and challenged the capacity of the health care system like no other event in modern times. While policy makers struggle with how to deploy and rebuild the public health infrastructure and the biomedical and pharma industries race to a vaccine and therapeutic cures, it is important to evaluate the best model for delivering care in the coming decades.
|
|
How ACOs in rural and underserved areas responded to Medicare's ACO investment model
Health Affairs
Implementation of accountable care organizations has been occurring unevenly across the nation, with rural areas lagging behind their more urban counterparts in ACO establishment. To help establish ACOs in more areas of the country, the Centers for Medicare and Medicaid Services developed the ACO Investment Model to provide participating ACOs with up-front and ongoing monthly payments over 24 months to fund ACO infrastructure investments and staffing.
|
|
.MANAGED HEALTHCARE NEWS
NORD report: COVID-19 telehealth surge especially important for people with rare diseases
Managed Healthcare Executive
Millions of Americans need continued access to telehealth services, especially those with rare disorders, many of which are autoimmune diseases, according to the National Organization for Rare Disorders.
“Currently, the Trump administration, Congress and state governments are trying to decide which changes to telehealth should be made permanent beyond the COVID-19 public health emergency,” NORD said in a new report, Ensuring Access to Telehealth for Rare Diseases.
|
|
Provider relief funds continue to flow into nation's health care system
Managed Healthcare Executive
So far in 2020, hospitals and other healthcare providers have received approximately $125 billion of the $175 billion allocated to the federal Provider Relief Fund to cover costs related to coronavirus care. This enormous injection of resources into the nation’s healthcare system has helped providers manage the costs related to the coronavirus, but it has also raised questions about the requirements for accepting and spending the funds.
|
|
.GENOMICS & BIOTECH
Researchers simulate privacy leaks in functional genomics studies
Cell Press via ScienceDaily
Researchers demonstrate that it's possible to de-identify raw functional genomics data to ensure patient privacy. They also demonstrate how these raw data could be linked back to specific individuals through their gene variants by something as simple as an abandoned coffee cup if these sanitation measures are not put in place.
|
|
|
 |
|
CTU’s new grant provides incoming students enrolling in the RN-BSN degree program 20% off tuition for those who apply and start courses by Jan. 5, 2021.
- Program costs starting at $9,984, with grant savings applied
- Save up to $2,496, with grant applied
- Available to apply from Oct. 1, 2020 – Jan. 5, 2021
|
|
Microbes' mystery DNA helps defeat viruses — and has genome-editing potential
AAAS via Science Magazine
Seven years ago, an understanding of nature inspired a revolutionary new technology, when researchers turned a defense system used by bacteria to thwart viruses into the gene-editing tool now known as CRISPR. But for another emerging gene editor the understanding has lagged the applications.
|
|
|
 |
|
Apollo delivers evidence-based guidelines in an easy to use format, available 24/7 from any internet-connected device. No software download required. Streamline utilization reviews and lower your costs today. Click here to begin your risk-free trial, or call to learn more! 888.276.5563
|
|
Some of our DNA functions exactly like a sea sponge's, which could solve a genetic mystery
SYFY WIRE
Of all things, a jelly-ish sea sponge is giving scientists more insight into an elusive part of the human genome.
This isn’t a horror movie about some hybrid gone wrong. We actually share important genetic mechanisms with these creatures (however unlikely that sounds). What could we possibly have in common with amorphous blobs that don’t even have a brain?
|
|
|
|
.BEHAVIORAL HEALTH
|
Promoted by TOLMAR Pharmaceuticals, Inc
Tolmar Affirms Supply of FENSOLVI® (leuprolide acetate) for Pediatric Patients with Central Precocious Puberty; Company increases U.S. manufacturing capacity of drug to ensure uninterrupted supply amid industry shortage
|
|
|
Mental health strained by disaster
University of Delaware via ScienceDaily
A new study found that suicide rates increase during all types of disasters — including severe storms, floods, hurricanes and ice storms — with the largest overall increase occurring two years after a disaster. A team of researchers examined the impact of 281 natural disasters on suicide rates during a 12-year span and found overall suicide rates increased by 23% when compared to rates before and after the disaster.
|
|
.NAMCP UPDATES
| | |
| LivaNova PLC, a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy®) to treatment as usual (TAU) significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD). The study examined patients from a five-year prospective registry and found 63% of TRBD patients treated with adjunctive VNS Therapy in addition to TAU had a significant reduction in depressive symptoms, as measured by a 50% or greater reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with 39% of patients in the TAU alone group. Click here to view the entire press release. Click here to view the entire press release.
|
| Additionally, LivaNova PLC announced a publication in Contemporary Clinical Trials, which details the design for “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression” or the RECOVER clinical study. RECOVER is currently under way as part of a Coverage with Evidence Development framework of the U.S. Centers for Medicare & Medicaid Services’ (CMS) National Coverage Determination process. Click here to view the entire press release.
|
| In late 2018, the National Association of Managed Care Physicians (NAMCP) decided to create the Value Based Care Council (VBCC). The VBCC mission supports empowering medical directors with information and resources to assist them in making value based decisions that support achieving the Triple AIM of improved outcomes and the patient experience while reducing overall costs. The goal is to improve the integration of cost, quality, and access in the clinical decision making process so as to enhance the effectiveness and efficiency of extracting value from the associated spend in order to optimize outcomes.
Pursuant to the above, and in response to an unmet need in the marketplace, the VBCC developed a short form in order to enhance the effectiveness and efficiency with which value propositions can be shared between industry and the medical leadership of various payers throughout the country. This same short form provides a concise and consistent manner with which value propositions can be shared and provides the ability to align expectations prior to actually conducting conversations or having a meeting regarding a product or service.
The Product Value Proposition Customer Engagement Short Form can be found on the NAMCP website (www.namcp.org) in the Value Based Care Council subsection of the Councils tab, under tools and resources. Please contact Will Williams at wwilliams@namcp.org with questions or for additional information.
|
| Jazz Pharmaceuticals is excited to announce the approval of ZEPZELCA™ (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. ZEPZELCA is a second-line therapy that has been studied in both platinum-sensitive and -resistant SCLC patients. Please click here for more information.
|
| Takeda Pharmaceuticals is part of, "The Fight Is In Us", an initiative to maximize the individual and societal benefit of COVID-19 plasma. The campaign will focus on recruiting COVID-19 survivors to donate their plasma at licensed blood and plasma donor centers.- If you’ve recovered from #COVID19, your immune system has antibodies that could be used as a treatment. See if you can help others by donating plasma www.TheFightIsInUs.org. #TheFightIsInUS
- The antibodies that helped you or someone you know fight off COVID-19 may be able to help others. Visit www.TheFightIsInUs.org to see if you qualify to donate plasma. #TheFightIsInUs
You are a survivor, now you could be a hero. Plasma from recovered #COVID19 patients could play a key role in creating a potential therapy for coronavirus. Learn how you can donate at www.TheFightIsInUs.org #TheFightIsInUs
|
| Biodesix, Inc., a leading diagnostic company in lung disease, recently announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S. Two studies published this month, ahead of peer review, reported that ddPCR testing showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR. Biodesix currently has a focus on lung disease and offers other diagnostic testing for lung cancer utilizing the ddPCR platform.Click here for more information.
|
| "Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attack" was recently published in the Journal of Managed Care Pharmacy's February 2020 issue. Hereditary angioedema (HAE) is a rare disease that causes painful and potentially fatal episodes of swelling (attacks). HAE attacks can be unpredictable and the need to treat sudden attacks promptly and effectively is critical to minimize risk of hospitalization, morbidity, and mortality. A cost-effectiveness model was evaluated that considers evaluation of on-demand medications, healthcare utilization and patient well-being. For access to the publication, please click here.
|
| Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc. The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIO®) (avelumab). Development efforts will now focus on transferring the test into Biodesix's CLIA lab in Boulder, CO for clinical phase test validation. The new test was developed through retrospective analysis of the circulating proteome of cancer patients treated with the investigational drug candidate, utilizing the proprietary Biodesix Diagnostic Cortex™ artificial intelligence (AI) platform. Click here to read the full press release.
|
| The NAMCP Medical Directors Institute recently held the first meeting of its Executive Leadership Council (ELC) at the recent Fall Managed Care Forum. The NAMCP Medical Directors Institute decided in late 2018 to create the Value Based Care Council (VBCC) with a mission to empower medical directors with information and resources to assist them in making value based decisions that support achieving the Triple AIM of improved outcomes and the patient experience while reducing overall costs. Click here to view an overview of the genesis, formation, and work of NAMCP's Value Based Care Council. Please click here to view the press release.
|
| LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient enrolled in "A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression" (RECOVER). The study will evaluate Vagus Nerve Stimulation Therapy (VNS Therapy) for Treatment-Resistant Depression (TRD) in accordance with the U.S. Centers for Medicare & Medicaid Services (CMS) National Coverage Determination as part of its Coverage with Evidence Development Program. The first patient was enrolled by Dr. Azfar Malik in St. Louis. Click here to read the full press release.
|
| Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test as a predictive biomarker for patient survival outcomes and as a diagnostic tool to improve the clinical management of patients with non-small cell lung cancer (NSCLC). This information is vital to implementing optimal treatment strategies for patients and supports disease state monitoring. To date, VeriStrat testing has helped more than 50,000 patients in determining the best treatment for their lung cancer. Click here to see the full press release. | |
|
|
|
 7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|